ArticleFrontiers in pharmacology2023

Comparison of bleeding risk and hypofibrinogenemia-associated risk factors between tigecycline with cefoperazone/sulbactam therapy and other tigecycline-based combination therapies.

Lei Zhang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.